Tadalafil
FDA-approved product (tablet, oral), marketed as Adcirca, Alyq, Chewtadzy and 3 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Benign prostatic hyperplasia
- Erectile dysfunction
- Impotence
- Pulmonary arterial hypertension
- Pulmonary hypertension
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Drugs used in erectile dysfunction
- FDA pharmacologic class
- Phosphodiesterase 5 Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae23.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Tadalafil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study the Safety and Effectiveness of Tadalafil in Men With Diabetes Who Have Problems Getting and Keeping an Erection
NCT00547183 · start 2004-10
Registered record
- Registry ID
- NCT00547183
- Conditions
- Impotence
- Interventions
- tadalafil; tadalafil; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-10
- Completion
- 2005-05
- Enrolment
- 298
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImpotenceInterventiontadalafil; tadalafil; placeboPhasePhase 3Registry statusCompletedA Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction
NCT00381732 · start 2003-10
Registered record
- Registry ID
- NCT00381732
- Conditions
- Erectile Dysfunction
- Interventions
- tadalafil; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-10
- Completion
- 2006-06
- Enrolment
- 280
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventiontadalafil; placeboPhasePhase 3Registry statusCompletedTo Determine Effect and Safety of Tadalafil Taken by Men of Different Races and With Different Diseases When Needed for Erections
NCT00547417 · start 2003-07
Registered record
- Registry ID
- NCT00547417
- Conditions
- Impotence
- Interventions
- tadalafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-07
- Completion
- 2004-03
- Enrolment
- 1,933
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImpotenceInterventiontadalafilPhasePhase 3Registry statusCompletedDetermine Safety and Effectiveness of Tadalafil in Asian Men When Taken as Needed for Getting and Keeping an Erection
NCT00547573 · start 2003-04
Registered record
- Registry ID
- NCT00547573
- Conditions
- Impotence
- Interventions
- tadalafil; tadalafil; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-04
- Completion
- 2003-12
- Enrolment
- 367
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImpotenceInterventiontadalafil; tadalafil; placeboPhasePhase 3Registry statusCompletedDetermine If the Stress That Comes With Not Developing an Erection Affects Tadalafil Effects
NCT00547599 · start 2003-04
Registered record
- Registry ID
- NCT00547599
- Conditions
- Impotence
- Interventions
- tadalafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2003-04
- Completion
- 2004-01
- Enrolment
- 659
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImpotenceInterventiontadalafilPhasePhase 4Registry statusCompleted